Hetero Ring Containing Patents (Class 514/172)
  • Patent number: 10421773
    Abstract: Oxysterol-bisphosphonate and oxysterol-alendronic acid compounds, compositions including them, and methods using them for the treatment of bone disorders.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: September 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Farhad Parhami, Frank Stappenbeck, Brian T. Chamberlain
  • Patent number: 10285951
    Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: May 14, 2019
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Leon Wan, Winnie Lui, Paul Tardi, Lawrence Mayer
  • Patent number: 10246482
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 2, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 10208081
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 19, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Jiang Long, Peng Dai, Xuechao Xing, Jing He
  • Patent number: 10093695
    Abstract: The present disclosure discloses a sterol derivative, a preparation method therefor and a use thereof. The sterol derivative includes a sterol compound with Structural Formula (I) or a pharmaceutically acceptable salt thereof, or an extract containing the sterol compound, or a composition containing the sterol compound, wherein Structural Formula (I) is as follows: where R1 is —OH, ?O, H or C1-C3 alkyl; R2 is —OH, H or C1-C3 alkyl; R3 is —OH, ?O, H or C1-C3 alkyl; R4 is —OH, H or C1-C3 alkyl, and at least one of R1, R2, R3 and R4 is —OH. The compound with Structural Formula (I) can be used for preparing a drug having inhibitory effect on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity and the prepared drug can effectively inhibit the HMG-CoA reductase activity or be used for preparing an anti-cancer drug.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: October 9, 2018
    Assignee: BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD.
    Inventors: Zhenwen Duan, Shuren Guo, Xuemei Li
  • Patent number: 10029034
    Abstract: The present invention relates to drug-eluting articles with multiple polymeric coatings arranged and constructed to provide improved drug release profiles. Specifically, the present invention relates to drug-eluting articles that each comprises a substrate, a first polymeric layer over said substrate, and a second polymeric layer over said first polymeric layer. The first polymeric layer comprises at least a first biocompatible polymer and at least a first pharmacologically active compound that is encapsulated in the first biocompatible polymer. The second polymeric layer comprises at least a second biocompatible polymer having a degradability that is higher than that of the first biocompatible polymer.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: July 24, 2018
    Assignee: Cardinal Health Switzerland 515 Gmbh
    Inventors: Robert Falotico, Jonathon Z. Zhao
  • Patent number: 9988417
    Abstract: The invention relates to a process for obtaining Estetrol or a salt or solvate thereof, the process comprising: a) reacting a compound of formula (IV) or a salt or solvate thereof, wherein R1 is a hydroxyl protecting group selected from a silyl ether, an ether, an ester, a carbamate and a carbonate, and R2 is a hydroxyl protecting group selected from an ether, with an oxidizing agent selected from OsO4 or a source of osmium tetroxide to produce Estetrol or a compound of formula (II) or a salt or solvate thereof wherein R1 is as defined previously; and b) if a compound of formula (II) is obtained in step a), deprotecting said compound to produce Estetrol.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Crystal Pharma, S.A.U.
    Inventors: Juan José Ferreiro Gil, Jesús Miguel Iglesias Retuerto, Francisco Javier Gallo Nieto
  • Patent number: 9958459
    Abstract: Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 1, 2018
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Ye Jin, Terry Hermiston, John Murphy
  • Patent number: 9920090
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 20, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Alicia Regueiro-Ren, Animesh Goswami, Zhiwei Guo, Thomas P. Tully, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell
  • Patent number: 9896474
    Abstract: (3?,9?,10?,13?,14?,17?,20S,22E)-Ergosta-5,7,22-trien-3-ol. A method for preparing the same by drying a fruiting body of Cordyceps militaris, grinding the fruiting body to yield ultrafine powders; boiling and extracting the ultrafine powders, centrifuging and collecting a precipitate. A method for treating a tumor by administering to a patient in need of treating a tumor (3?,9?,10?,13?,14?,17?,20S,22E)-ergosta-5,7,22-trien-3-ol.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 20, 2018
    Assignee: ZHENGYUANTANG (TIANJIN BINHAI NEW AREA) BIOTECH CO., LTD.
    Inventors: Yaozhou Zhang, Jiachen Sun, Lei Jiang, Jian Zhang, Yujiao Chen, Xiaoqian Zhang, Simiao Du, Pengai Gu, Jinsong Cui
  • Patent number: 9868757
    Abstract: Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 16, 2018
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Patrizia Ferrari, Giuseppe Bianchi, Mara Ferrandi
  • Patent number: 9707223
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 18, 2017
    Assignee: CORCEPT THERAPEUTICS, INC.
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • Patent number: 9439912
    Abstract: The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: September 13, 2016
    Assignee: University of Maryland, Baltimore
    Inventors: Vincent C. O. Njar, Lalji K. Gediya, Puranik Purushottamachar, Abhijit Godbole, Andrew Kwegyir-Afful, Tadas Vasaitis
  • Patent number: 9433631
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 6, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Patent number: 9144569
    Abstract: Described herein are methods for synchronizing ovulation in a herd, inducing superovulation in a single animal, and improving frequency of successful implantation and development of fertilized ova.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: September 29, 2015
    Assignee: UNIVERSITY OF SASKATCHEWAN
    Inventors: Roger Pierson, Gregg Adams
  • Patent number: 9127037
    Abstract: New crystalline forms of 17?-(3-Furyl)-5-?androstane-3?,14?,17?-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: September 8, 2015
    Assignee: ROSTAQUO S.P.A.
    Inventors: Alberto Cerri, Silvia Armaroli, Marco Torri
  • Publication number: 20150126464
    Abstract: A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D3-MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.
    Type: Application
    Filed: July 24, 2013
    Publication date: May 7, 2015
    Inventor: Chihiro Tohda
  • Patent number: 9017956
    Abstract: Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of Cryptococcus neoformans, roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: April 28, 2015
    Assignee: Nutrex Technology Co., Ltd.
    Inventors: Yong-Sun Bahn, Young-Joon Ko, Shin-Ae Maeng, Kwang Woo Jung, Gyu Bum Kim
  • Patent number: 9017728
    Abstract: Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: April 28, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Publication number: 20150099712
    Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
    Type: Application
    Filed: May 9, 2013
    Publication date: April 9, 2015
    Inventors: Chun Liang, Zhihong Jiang, Ziyi Wang, Zhiling Yu, Jingrong Wang, Liping Bai
  • Publication number: 20150093423
    Abstract: Particulate ceragenin materials may be manufactured by (i) providing a ceragenin feed material comprised of ceragenin molecules, each having a sterol backbone and a plurality cationic groups attached thereto; (ii) fracturing the ceragenin feed material in a milling apparatus to produce a ceragenin particulate material having a particle size distribution with a median particle size in a range from 5 nm to 20 ?m; and (iii) during fracturing, maintaining the ceragenin feed with a moisture content of less than or equal to 10% by weight.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 2, 2015
    Applicant: Brigham Young University
    Inventors: Paul B. Savage, Carl Genberg
  • Publication number: 20150093455
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
    Type: Application
    Filed: June 24, 2014
    Publication date: April 2, 2015
    Inventors: Calvin Bruce HARLEY, Allison C. CHIN, Tsutomu AKAMA, Nancy Yuk-Yu IP, Yung-Hou WONG, David M. MILLER-MARTINI
  • Publication number: 20150057258
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Publication number: 20150050367
    Abstract: Provided herein are timosaponin compounds of Formula I, II, III, I?, II? and III?, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for preparing medicament for the treatment of diseases associated with beta-amyloid in hosts or subjects in need thereof.
    Type: Application
    Filed: April 2, 2013
    Publication date: February 19, 2015
    Inventors: Chiming Che, Laiking Sy, Chunnam Lok
  • Publication number: 20150031657
    Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.
    Type: Application
    Filed: December 25, 2012
    Publication date: January 29, 2015
    Inventors: Zhenwen Duan, Shuren Guo, Xuemei Li
  • Patent number: 8916171
    Abstract: A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area. This reduces the amount of wasted medication that would otherwise result from other topical methods.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: December 23, 2014
    Assignee: Topical Sinus Therapeutics, Inc.
    Inventors: Russell N. Reitz, Robert Scott Osbakken
  • Patent number: 8906892
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Patent number: 8906392
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: December 9, 2014
    Assignee: University of Kansas
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20140357607
    Abstract: The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Inventors: Robert Lathrop, David Wade Osborne
  • Publication number: 20140343023
    Abstract: The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.
    Type: Application
    Filed: September 18, 2012
    Publication date: November 20, 2014
    Inventors: Christian Wolfrum, Erick Carriera, Bettina Meissburger
  • Patent number: 8889840
    Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 18, 2014
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young-Guen Kwon, Young-Ger Suh
  • Patent number: 8853194
    Abstract: Sterol derivatives with structural formula I or II are disclosed, wherein R is defined as the description of the invention. Their synthesizing methods and anti-tumor use are also disclosed. Especially, the compound of formula I, in which R is O (i.e. the compound CL 168-6), has the anti-tumor therapeutic index of 49.3. The compound can be used to prepare a medicine for prevention or treatment of immunological diseases and cancers such as liver cancer and lung cancer.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 7, 2014
    Inventors: Dagang Chen, Haimin Lei
  • Publication number: 20140271761
    Abstract: A method and kit for manufacturing a composite that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 ?m, 50 nm to 10 ?m, 100 nm to 5 ?m, or 1 ?m to 10 ?m. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 18, 2014
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: PAUL B. SAVAGE, Carl Genberg
  • Patent number: 8822441
    Abstract: This invention discloses a novel compound with the structure of formula I, or pharmaceutically acceptable salts or solvates thereof. In addition, the invention further discloses a method for preparing the compound, a pharmaceutical composition containing the compound, and use thereof in the preparation of a hypoglycemic medicament.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: September 2, 2014
    Assignee: Chongqing Zen Pharmaceutical Co., Ltd.
    Inventors: Yongpeng Xia, Xiaolin Wang, Yong Qin, Zongyin Qiu, Lirong Xu, Min Zhang, Dan Zhang, Bao Ding, Qiu Chen
  • Publication number: 20140242171
    Abstract: Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Applicant: GALENICA AB
    Inventors: Henri Hansson, Anna Karin Morén
  • Publication number: 20140228332
    Abstract: The present invention provides a method for enhancing the secretion of GLP-1 of the intestinal endocrine L-cells using a bitter compound, wherein the bitter compound is a cucurbitane-triterpenoid or allyl isothiocyanate. The bitter compound can regulate the secretion of GLP-1, thus is potentially reliable for the development of medicament or healthy victual.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 14, 2014
    Applicant: National Taiwan University
    Inventors: Ching-jang Huang, Yi-ping Pai, Ting-ni Huang
  • Patent number: 8802662
    Abstract: The invention provides an anti-hepatitis C composition including: an effective amount of limonoid compound, wherein the structure of the limonoid compound is shown as Structure (I): where R1 comprises H or OAc and R2 comprises H or COCH(CH3)2; and a pharmaceutically acceptable carrier or salt, and the anti-hepatitis C composition is used for inhibiting hepatitis C virus or treating hepatitis C. The invention also provides a method for treating hepatitis C and a method for preparing a drug for inhibiting hepatitis C viruses or treating hepatitis C.
    Type: Grant
    Filed: October 4, 2009
    Date of Patent: August 12, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Lain-Tze Lee, Shau-Feng Chang, Hui-Ping Tsai, Zong-Keng Kuo, Chen-Fang Chung
  • Patent number: 8802661
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: August 12, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Nicholas A. Meanwell, Sing-Yuen Sit, Jie Chen, Yan Chen, Ny Sin
  • Publication number: 20140206749
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Applicant: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Patent number: 8785425
    Abstract: The invention provides 11?-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein R4 represents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C), Z is S:
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 22, 2014
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Samir Rameshchandra Shah, Sanjay Nandlal Mandhane, Trinadha Rao Chitturi, Rajamannar Thennati
  • Publication number: 20140199297
    Abstract: In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving modification with polyethylene glycol and (b) a formulation approach involving non-covalent encapsulation in antibody targeted pol(DL-lactic acid) nanoparticles.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 17, 2014
    Applicant: Research Foundation of the City University of New York
    Inventors: Linda Saxe Einbond, Krishnaswami Raja
  • Publication number: 20140200203
    Abstract: Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
    Type: Application
    Filed: May 13, 2011
    Publication date: July 17, 2014
    Inventors: Fritjof Evers, Henning Mallwitz, Ricarda Wessel, Christoph Willers
  • Publication number: 20140186278
    Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 3, 2014
    Inventor: Patrick Franke
  • Publication number: 20140186417
    Abstract: An aliphatic polyester polymer for stent coating is described.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 3, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: O. Mikael Trollsas, Lothar W. Kleiner, Syed F.A. Hossainy
  • Patent number: 8759330
    Abstract: Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the ?-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: June 24, 2014
    Assignee: Washington University
    Inventors: Douglas F. Covey, Xin Jiang
  • Patent number: 8754068
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: June 17, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alicia Regueiro-Ren, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell, Sing-Yuen Sit, Jie Chen, Ny Sin
  • Patent number: 8748415
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: June 10, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alicia Regueiro-Ren, Jacob Swidorski, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell, Zheng Liu
  • Publication number: 20140135302
    Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 15, 2014
    Applicant: SOMALOGIC, INC.
    Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
  • Patent number: 8722651
    Abstract: The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 13, 2014
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Publication number: 20140088055
    Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.
    Type: Application
    Filed: July 8, 2013
    Publication date: March 27, 2014
    Applicant: TELOMERASE ACTIVATION SCIENCES, INC.
    Inventors: Calvin Bruce HARLEY, Soo-Peang KHOR, Mahesh RAMASESHAN, Premchandran H. RAMIYA, Zhu Z. PIROT, Steven FAUCE, Tong LIN